European approval for Glyxambi

25 November 2016

Adding to US approval early last year for their combination diabetes product, German family-owned drug major Boehringer Ingelheim and USA-based Eli Lilly (NYSE: LLY) have received clearance to market it in Europe.

The companies announced that Glyxambi (empagliflozin/linagliptin) has been granted marketing authorisation by the European Commission for use in adults with type 2 diabetes (T2D). Glyxambi is a single pill combining Jardiance (empagliflozin), a sodium glucose co-transporter-2 (SGLT2) inhibitor, and Trajenta (linagliptin), a dipeptidyl peptidase-4 (DPP-4) inhibitor.

Glyxambi is approved for use in adults with T2D to improve blood sugar control when metformin and/or sulphonylurea and one of the monocomponents of Glyxambi do not provide adequate blood sugar control, or when a patient is already being treated with the free combination of Jardiance and Trajenta.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK